Jupiter Neurosciences doses first patient in Phase 2a Parkinson’s trial and explores strategic options
JUNS•Jupiter Neurosciences said the first patient has been dosed in its Phase 2a RESET trial in Parkinson’s disease and that it has begun a formal process to explore strategic options.
1. Trial and strategic review
Jupiter Neurosciences announced the first patient was dosed in its Phase 2a RESET trial in Parkinson’s disease. The company also said it has initiated a formal process to explore strategic options to maximize shareholder value.
